tenofovir has been researched along with Obesity in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 6 (60.00) | 2.80 |
Authors | Studies |
---|---|
Campins, AA; García Fraile, LJ; Martínez-Sanz, J; Mena de Cea, Á; Moreno, S; Muriel, A; Orviz, E; Serrano-Villar, S | 1 |
Abgrall, S; Allavena, C; Bernard, L; Bregigeon, S; Caby, F; Capeau, J; Costagliola, D; de Truchis, P; Duvivier, C; Enel, P; Grabar, S; Katlama, C; Khuong, MA; Launay, O; Matheron, S; Melica, G; Melliez, H; Meynard, JL; Pavie, J; Piroth, L; Potard, V; Slama, L; Tattevin, P | 1 |
El Kamari, V; Hileman, CO; Kosco, J; Mccomsey, GA | 1 |
Bernasconi, E; Calmy, A; Cavassini, M; Furrer, H; Günthard, HF; Ledergerber, B; Mugglin, C; Rauch, A; Schmid, P; Stöckle, M; Surial, B; Tarr, PE; Wandeler, G | 1 |
Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
Baettig, V; Battegay, M; Courlet, P; Delko, T; Marzolini, C | 1 |
Blackhurst, D; De Boever, P; Everson, F; Genis, A; Goswami, N; Lochner, A; Ogundipe, T; Strijdom, H | 1 |
Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
Grome, H; Jenkins, CA; Kalams, SA; Koethe, JR; Sterling, TR | 1 |
1 review(s) available for tenofovir and Obesity
Article | Year |
---|---|
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
1 trial(s) available for tenofovir and Obesity
Article | Year |
---|---|
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
8 other study(ies) available for tenofovir and Obesity
Article | Year |
---|---|
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV-1; Humans; Hypertension; Lipids; Male; Obesity; Prospective Studies; Tenofovir; Triglycerides | 2023 |
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; HIV Infections; Humans; Obesity; Tenofovir; Weight Gain | 2023 |
Sleeve Gastrectomy Compared With Roux-en-Y Gastric Bypass in Individuals Living With HIV.
Topics: Adult; Atazanavir Sulfate; Body Mass Index; Gastrectomy; Gastric Bypass; HIV Infections; Humans; Middle Aged; Obesity; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
Topics: Adult; Alanine; Anti-HIV Agents; HIV Infections; Humans; Lipids; Obesity; Tenofovir; Weight Gain | 2021 |
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Topics: Adult; Alanine; Anti-HIV Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; Humans; Lipids; Male; Middle Aged; Obesity; Sensitivity and Specificity; Tenofovir; Triglycerides; Weight Gain | 2021 |
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bariatric Surgery; Chromatography, Liquid; Darunavir; Emtricitabine; Female; Gastric Bypass; HIV Infections; Humans; Obesity; Plasma; Tandem Mass Spectrometry; Tenofovir | 2018 |
Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats.
Topics: Alkynes; AMP-Activated Protein Kinases; Animals; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diet, High-Fat; Drug Therapy, Combination; Emtricitabine; Heart; Male; Myocardium; Nitric Oxide Synthase Type III; Obesity; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Reperfusion Injury; Tenofovir | 2018 |
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cohort Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Male; Metabolic Diseases; Middle Aged; Obesity; Risk Assessment; Tenofovir | 2016 |